• français 
    • español
    • English
    • français
  • FacebookPinterestTwitter
  • español
  • English
  • français
Voir le document 
  •   Accueil de DIGIBUG
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • Voir le document
  •   Accueil de DIGIBUG
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.

A P(V) platform for oligonucleotide synthesis

[PDF] Articulo principal (2.331Mo)
Identificadores
URI: https://hdl.handle.net/10481/101157
DOI: 10.1126/science.abi9727
Exportar
RISRefworksMendeleyBibtex
Estadísticas
Statistiques d'usage de visualisation
Metadatos
Afficher la notice complète
Auteur
Huang, Yazhong; Knouse, Kyle W.; Qiu, Shenjie; Hao, Wei; Vantourout, Julien C.; Zheng, Bin; Mercer, Stephen E.; Lopez-Ogalla, Javier; Narayan, Rohan; Olson, Richard E.; Blackmond, Donna G.; Eastgate, Martin D.; Schmidt, Michael A.; McDonald, Ivar M.; Baran, Phil S.; Muñoz Padial, Natalia
Editorial
American Association for the Advancement of Science: AAAS, USA.
Date
2021-09-10
Referencia bibliográfica
Science, 2021, 373, 1265–1270
Patrocinador
We thank D.-H. Huang and L. Pasternack (Scripps Research) for assistance with NMR spectroscopy; J. Chen (Automated Synthesis Facility, Scripps Research) for purification of compounds and acquisition of HRMS data; A. L. Rheingold, C. E. Moore, and M. Gembicky (UCSD) for x-ray analysis; and S. Mukherjee (BMS) for calculating the process mass intensity. Funding: This work was supported by Bristol Myers Squibb, NIGMS (GM106210), NIH (grant number GM-118176), Marie Skłodowska-Curie Global Fellowships (749359-EnanSET, N.M.P) within the European Union research and innovation framework program (2014-2020), and the NSF SURF Program (TSRI, R.N).
Résumé
The promise of gene-based therapies is being realized at an accelerated pace, with more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides, by far most of which contain modified phosphate linkages. These unnatural linkages have desirable biological and physical properties but are often accessed with difficulty using phosphoramidite chemistry. We report a flexible and efficient [P(V)]–based platform that can install a wide variety of phosphate linkages at will into oligonucleotides. This approach uses readily accessible reagents and can install not only stereodefined or racemic thiophosphates but any combination of (S, R or rac)–PS with native phosphodiester (PO2) and phosphorodithioate (PS2) linkages into DNA and other modified nucleotide polymers. This platform easily accesses this diversity under a standardized coupling protocol with sustainably prepared, stable P(V) reagents.
Colecciones
  • FQM339 - Artículos

Mon compte

Ouvrir une sessionS'inscrire

Parcourir

Tout DIGIBUGCommunautés et CollectionsPar date de publicationAuteursTitresSujetsFinanciaciónPerfil de autor UGRCette collectionPar date de publicationAuteursTitresSujetsFinanciación

Statistiques

Statistiques d'usage de visualisation

Servicios

Pasos para autoarchivoAyudaLicencias Creative CommonsSHERPA/RoMEODulcinea Biblioteca UniversitariaNos puedes encontrar a través deCondiciones legales

Contactez-nous | Faire parvenir un commentaire